Gutierrez Samantha Anne S, Yu Jeryl Ritzi T, Yalung Patrick M, Jamora Roland Dominic G
Section of Neurology, Institute for Neurosciences, St. Luke's Medical Center, Quezon City, Philippines.
Section of Neurology, Institute for Neurosciences, St. Luke's Medical Center, Quezon City, Philippines; Movement Disorders Service and Section of Neurology, Institute for Neurosciences, St. Luke's Medical Center, Quezon City, Philippines; Department of Neurosciences, College of Medicine - Philippine General Hospital, University of the Philippines Manila, Philippines; Movement Disorders Service and Section of Neurology, Institute for Neurosciences, St. Luke's Medical Center, Global City, Philippines.
Clin Neurol Neurosurg. 2021 Jun;205:106632. doi: 10.1016/j.clineuro.2021.106632. Epub 2021 Apr 2.
Hemifacial spasm (HFS) is a chronic, potentially disabling disorder that often requires long-term management with botulinum toxin (BoNT). In a country where healthcare costs limit compliance to medical follow-up and treatment, the study aims to provide a real-world experience on the use of BoNT for HFS among Filipinos.
We retrospectively collected data from 162 HFS patients who received 1138 botulinum toxin (BoNT) injections from 2006 to 2019 in our movement disorders center in the Philippines. We described their clinical profile and treatment response.
The mean age at onset of disease was 47.7 ± 10.72 years. Majority of the patients reported a baseline moderate disease severity and disease frequency of >75% of waking time (59.8% and 46.9%, respectively). Most patients (61.73%) received 5 or less injections during the follow-up period. The mean duration of follow-up was 2.96 ± 4.28 years. The overall duration of treatment effect per injection was 3.6 ± 1.3 months while the mean interval between injections was 6 ± 5 months. There was no difference in the symptom improvement and duration between onabotulinumtoxinA and abobotulinumtoxinA. Side effects were infrequent.
This study supports existing evidence on the efficacy and safety of BoNT for the symptomatic relief of HFS. In the Philippines, long-term treatment with BoNT may be limited by the cost of the procedure as majority of our patients had a few injections with long treatment intervals.
面肌痉挛（HFS）是一种慢性、可能导致残疾的疾病，通常需要使用肉毒杆菌毒素（BoNT）进行长期治疗。在一个医疗费用限制了患者接受医学随访和治疗依从性的国家，本研究旨在提供关于菲律宾人使用BoNT治疗HFS的真实世界经验。
我们回顾性收集了2006年至2019年期间在菲律宾我们的运动障碍中心接受1138次肉毒杆菌毒素（BoNT）注射的162例HFS患者的数据。我们描述了他们的临床特征和治疗反应。
疾病发病的平均年龄为47.7±10.72岁。大多数患者报告基线疾病严重程度为中度，且疾病发作频率在清醒时间的75%以上（分别为59.8%和46.9%）。大多数患者（61.73%）在随访期间接受了5次或更少的注射。平均随访时间为2.96±4.28年。每次注射的治疗效果总持续时间为3.6±1.3个月，而注射之间的平均间隔为6±5个月。A型肉毒毒素和B型肉毒毒素在症状改善和持续时间方面没有差异。副作用很少见。
本研究支持了关于BoNT缓解HFS症状的疗效和安全性的现有证据。在菲律宾，BoNT的长期治疗可能受到治疗费用的限制，因为我们的大多数患者注射次数较少且治疗间隔较长。
